Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1976 1
1977 3
1979 1
1980 2
1982 4
1983 1
1984 1
1985 3
1986 1
1987 2
1988 1
1989 4
1990 1
1991 1
1992 7
1993 5
1994 6
1995 3
1996 9
1997 11
1998 13
1999 13
2000 13
2001 16
2002 14
2003 23
2004 19
2005 14
2006 23
2007 32
2008 28
2009 38
2010 31
2011 42
2012 44
2013 41
2014 28
2015 36
2016 33
2017 32
2018 31
2019 34
2020 41
2021 45
2022 57
2023 62
2024 31

Text availability

Article attribute

Article type

Publication date

PubMed for id: 344154

794 results

Results by year

Filters applied: . Clear all
Page 1
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Cork MJ, Lockshin B, Pinter A, Chen Z, Shumel B, Prescilla R. Cork MJ, et al. Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467. Acta Derm Venereol. 2024. PMID: 38348724 Free PMC article. Clinical Trial.
Dupilumab (Dupixent): CADTH Reimbursement Recommendation: Indication: For the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct. Report No.: SR0774. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct. Report No.: SR0774. PMID: 38096354 Free Books & Documents. Review.
794 results